BFM
EPRX

Boothbay Fund Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Boothbay Fund Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
212,653
-111,190
-34% -$767K 0.02% 907
2026
Q1 		$2.34M Buy
323,843
+167,512
+107% +$1.35M 0.03% 552
2025
Q4 		$1.18M Buy
+156,331
New +$963K 0.02% 737

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management's EPRX Position: Q2 2026 in Review

Boothbay Fund Management reduced its Eupraxia Pharmaceuticals (EPRX) stake by 34% in Q2 2026, selling an estimated $767K and leaving 212,653 shares worth $1.41M. The position accounts for 0.02% of the portfolio, ranked #907.

Boothbay Fund Management first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.34M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Boothbay Fund Management held 212,653 shares of Eupraxia Pharmaceuticals worth $1.41M as of Q2 2026.
  • Boothbay Fund Management sold 111,190 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $767K.
  • Eupraxia Pharmaceuticals made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #907 holding.
  • Boothbay Fund Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's Eupraxia Pharmaceuticals position peaked at $2.34M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.